Vanda Pharmaceuticals Q2 revenue up 4%
Overview
Vanda Q2 revenue rises 4% yr/yr to $52.6 mln, no analyst estimate provided
Net loss widens to $27.2 mln in Q2 from $4.5 mln in Q2 2024
Fanapt revenue grows 27% yr/yr, driven by sales efforts and brand campaign
Outlook
Vanda expects 2025 revenue between $210 mln and $250 mln
Company forecasts year-end 2025 cash between $280 mln and $320 mln
Vanda anticipates continued Fanapt revenue growth in coming quarters
Company expects significant regulatory milestones in coming months
Result Drivers
FANAPT SALES GROWTH - Driven by expanded sales efforts and direct-to-consumer brand awareness campaign
REGULATORY MILESTONES - Significant upcoming milestones expected to strengthen commercial portfolio
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| $52.59 bln |
|
Q2 Adjusted EPS |
| -$0.46 |
|
Q2 EPS |
| -$0.46 |
|
Q2 Net Income |
| -$27.21 mln |
|
Q2 Basic EPS |
| -$0.46 |
|
Q2 Operating Expenses |
| $91.09 mln |
|
Q2 Operating Income |
| -$38.50 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $13.00, about 64.1% above its July 30 closing price of $4.67
Press Release: ID:nPn50CMm9a
